Astrocyte Pharmaceuticals, Inc.
Astrocyte Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative neuroprotection therapies for traumatic brain injuries (TBI), concussions, stroke, and neurodegenerative disorders. The company focuses on harnessing the potential of astrocytes, the brain's natural caretaker cells, to treat brain injuries and diseases. Their flagship program, AST-004, aims to significantly reduce early brain damage and is advancing to Phase 2 clinical trials.
Industries
Nr. of Employees
small (1-50)
Astrocyte Pharmaceuticals, Inc.
93 Shennecossett Road, Groton, CT 06340
Patents
Compounds and methods for treating neurological and cardiovascular conditions
US-12390483-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-12239654-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-10953031-B2
View Details
Compounds and methods for treating neurological and cardiovascular conditions
US-12390483-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-12239654-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-11484545-B2
View DetailsCompounds and methods for treating neurological and cardiovascular conditions
US-10953031-B2
View DetailsProducts
Lead small-molecule adenosine A1/A3 receptor agonist candidate (cerebroprotective)
Clinical-stage small-molecule therapeutic candidate that activates astrocyte energy metabolism via receptor-mediated IP3/Ca2+ signaling to enhance mitochondrial ATP production and reduce acute brain injury; developed as an intravenous formulation for emergency administration with an oral formulation in preclinical development.
Additional small-molecule CNS candidates (preclinical)
Other CNS-directed small-molecule programs in preclinical development including candidates for pain/migraine and additional CNS indications.
Lead small-molecule adenosine A1/A3 receptor agonist candidate (cerebroprotective)
Clinical-stage small-molecule therapeutic candidate that activates astrocyte energy metabolism via receptor-mediated IP3/Ca2+ signaling to enhance mitochondrial ATP production and reduce acute brain injury; developed as an intravenous formulation for emergency administration with an oral formulation in preclinical development.
Additional small-molecule CNS candidates (preclinical)
Other CNS-directed small-molecule programs in preclinical development including candidates for pain/migraine and additional CNS indications.
Services
Conduct of efficacy studies across rodent and nonhuman primate models to evaluate lesion growth, edema, penumbra preservation, and neuronal survival.
Design and operational execution of early-phase clinical trials (Phase 1 safety studies completed; Phase 2 planning), including regulatory interactions.
Integration of unbound plasma, CSF concentrations and estimated receptor occupancy with efficacy endpoints to inform human dose selection.
Development of intravenous formulations for emergency administration and oral formulations for field or chronic use to support clinical and preclinical programs.
Conduct of efficacy studies across rodent and nonhuman primate models to evaluate lesion growth, edema, penumbra preservation, and neuronal survival.
Design and operational execution of early-phase clinical trials (Phase 1 safety studies completed; Phase 2 planning), including regulatory interactions.
Integration of unbound plasma, CSF concentrations and estimated receptor occupancy with efficacy endpoints to inform human dose selection.
Development of intravenous formulations for emergency administration and oral formulations for field or chronic use to support clinical and preclinical programs.
Expertise Areas
- Cerebroprotection and neuroprotection
- Translational preclinical neuroscience
- Clinical trial management for acute neurological indications
- Small-molecule drug discovery for central nervous system (CNS) targets
Key Technologies
- Adenosine receptor pharmacology (A1/A3-targeted agonists)
- IP3/Ca2+-mediated mitochondrial activation assays
- Nonhuman primate transient middle cerebral artery occlusion (tMCAO) model
- Rodent TBI models (pneumatic impact, photothrombosis)
News & Updates
Astrocyte Pharmaceuticals was named 'Innovator of the Month' by Senator Chris Murphy for their work in advancing cerebroprotective therapies.
Astrocyte Pharmaceuticals received FDA clearance for its Investigational New Drug Application for AST-004, paving the way for Phase 2 trials.
The Alzheimer’s Drug Discovery Foundation joined Astrocyte Pharmaceuticals’ $6M+ pre-Series B financing round to expand the development of AST-004.
Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Innovation and Progress Award from the journal Stroke for his work on AST-004.
Astrocyte Pharmaceuticals was named 'Innovator of the Month' by Senator Chris Murphy for their work in advancing cerebroprotective therapies.
Astrocyte Pharmaceuticals received FDA clearance for its Investigational New Drug Application for AST-004, paving the way for Phase 2 trials.
The Alzheimer’s Drug Discovery Foundation joined Astrocyte Pharmaceuticals’ $6M+ pre-Series B financing round to expand the development of AST-004.
Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Innovation and Progress Award from the journal Stroke for his work on AST-004.